Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 17270021)

1.

Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.

Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N.

Cancer Sci. 2007 Mar;98(3):321-8.

PMID:
17270021
2.

Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells.

Zhuang H, Zhao MY, Hei KW, Yang BC, Sun L, Du X, Li YM.

Asian Pac J Cancer Prev. 2015;16(8):3325-31.

3.

Periostin: a potent chemotactic factor for recruiting tumor-associated macrophage.

Wu T, Luo Q, Ouyang G.

Protein Cell. 2015 Apr;6(4):235-7. doi: 10.1007/s13238-015-0141-9. No abstract available.

5.

BAD-mediated apoptotic pathway is associated with human cancer development.

Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM.

Int J Mol Med. 2015 Apr;35(4):1081-7. doi: 10.3892/ijmm.2015.2091. Epub 2015 Feb 5.

6.

The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors.

Wurz RP, Pettus LH, Jackson C, Wu B, Wang HL, Herberich B, Cee V, Lanman BA, Reed AB, Chavez F Jr, Nixey T, Laszlo J 3rd, Wang P, Nguyen Y, Sastri C, Guerrero N, Winston J, Lipford JR, Lee MR, Andrews KL, Mohr C, Xu Y, Zhou Y, Reid DL, Tasker AS.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):847-55. doi: 10.1016/j.bmcl.2014.12.067. Epub 2015 Jan 7.

PMID:
25599837
7.

Understanding the functional discrepancy of Pim-1 in cancer.

Ouhtit A, Muzumdar S, Gupta I, Shanmuganathan S, Tamimi Y.

Front Biosci (Elite Ed). 2015 Jan 1;7:208-14.

PMID:
25553374
8.

New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.

Moreau P, Dezhenkova LG, Anizon F, Nauton L, Thery V, Liang S, Kaluzhny DN, Shtil AA.

Anticancer Agents Med Chem. 2014;14(9):1228-36.

PMID:
25175798
9.

Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.

Li YY, Mukaida N.

World J Gastroenterol. 2014 Jul 28;20(28):9392-404. doi: 10.3748/wjg.v20.i28.9392. Review.

10.

PIM kinases: an overview in tumors and recent advances in pancreatic cancer.

Xu J, Zhang T, Wang T, You L, Zhao Y.

Future Oncol. 2014 Apr;10(5):865-76. doi: 10.2217/fon.13.229. Review.

PMID:
24799066
11.

Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis.

Liu B, Wang Z, Li HY, Zhang B, Ping B, Li YY.

Oncol Rep. 2014 Jun;31(6):2625-34. doi: 10.3892/or.2014.3158. Epub 2014 Apr 25.

PMID:
24789328
12.

Immunotherapy for hepatoma using a dual-function vector with both immunostimulatory and pim-3-silencing effects.

Guo Q, Lan P, Yu X, Han Q, Zhang J, Tian Z, Zhang C.

Mol Cancer Ther. 2014 Jun;13(6):1503-13. doi: 10.1158/1535-7163.MCT-13-0722. Epub 2014 Apr 10.

13.

Serine threonine kinase Pim-3 regulates STAT3 pathway to inhibit proliferation of human liver cancers.

Wang J, Lao L, Zhao H, Huang Y.

Int J Clin Exp Med. 2014 Feb 15;7(2):348-55. eCollection 2014.

14.

Some technical problems associated with complicated malignant lesions of the colon.

HUNT CJ.

South Surg. 1950 Oct;16(10):986-95. No abstract available.

PMID:
24538797
15.

Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.

Garcia PD, Langowski JL, Wang Y, Chen M, Castillo J, Fanton C, Ison M, Zavorotinskaya T, Dai Y, Lu J, Niu XH, Basham S, Chan J, Yu J, Doyle M, Feucht P, Warne R, Narberes J, Tsang T, Fritsch C, Kauffmann A, Pfister E, Drueckes P, Trappe J, Wilson C, Han W, Lan J, Nishiguchi G, Lindvall M, Bellamacina C, Aycinena JA, Zang R, Holash J, Burger MT.

Clin Cancer Res. 2014 Apr 1;20(7):1834-45. doi: 10.1158/1078-0432.CCR-13-2062. Epub 2014 Jan 28.

16.

A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression.

Zhang F, Liu B, Wang Z, Yu XJ, Ni QX, Yang WT, Mukaida N, Li YY.

Mol Cancer Res. 2013 Dec;11(12):1508-20. doi: 10.1158/1541-7786.MCR-13-0389. Epub 2013 Oct 28.

17.

Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor.

Wang C, Li HY, Liu B, Huang S, Wu L, Li YY.

J Surg Res. 2013 Dec;185(2):595-604. doi: 10.1016/j.jss.2013.06.004. Epub 2013 Jun 28.

PMID:
23845873
18.

The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.

Ren K, Gou X, Xiao M, Wang M, Liu C, Tang Z, He W.

Prostate. 2013 Sep;73(13):1462-9. doi: 10.1002/pros.22693. Epub 2013 Jun 27.

PMID:
23813671
19.

Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.

Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, Baines AT.

Cancer Biol Ther. 2013 Jun;14(6):492-501. doi: 10.4161/cbt.24343.

20.

T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug.

Wang Z, Li XM, Shang K, Zhang P, Wang CF, Xin YH, Zhou L, Li YY.

Oncol Rep. 2013 Mar;29(3):1245-51. doi: 10.3892/or.2013.2233. Epub 2013 Jan 11.

PMID:
23314349
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk